We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image
  • Published On : Dec 2020
  • Code : CMI4326
  • Pages :175
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

A mental disorder is also called as mental illness or a psychiatric disorder. Mental disorders are generally defined according to how an individual behave, feels, perceives and thinks, and mental disorder occurs due to damage or problems associated with functions of brain. There are various types of mental disorders such as depression, bipolar disorder, schizophrenia and other psychoses, dementia, and developmental disorders including autism. These disorders can be treated with the help of various medications such as anti-depressants, antianxiety drugs and can also be treated with self-help therapies such as psychotherapy, brain stimulation treatments, and others.

The global mental disorder treatment market is estimated to be valued at US$ 48.4 Billion in 2020 and is expected to exhibit a CAGR of 6.6% during the forecast period (2020-2027).

Figure 1. Global Mental Disorder Treatment Market Value (US$ Bn), 2016-2027

MENTAL DISORDER TREATMENT MARKET

The increasing prevalence of mental disorders such as depression is expected to propel growth of the global mental disorder treatment market during the forecast period. For instance, according to the World Health Organization report published in 2019, stated that depression is the most common mental disorder globally and around 264 million individuals suffered from depression globally, in the year 2019.

Furthermore, key companies focusing on product approvals by regulatory bodies for the treatment of mental disorders is expected to propel growth of the global mental disorder treatment market during the forecast period. For instance, in May 2019, Allergan plc. and Gedeon Richter Plc. announced that the U.S. Food and Drug Administration (FDA) approved its VRAYLAR (cariprazine) as a supplemental new drug application (sNDA) for the treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults.

Hydroxychloroquine Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 48.4 Bn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 6.6% 2027 Value Projection: US$ 75.7 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of the Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Disorder Type: Depression, Bipolar Disorder, Schizophrenia, Dementia, Post-traumatic Stress Disorder, Others.
  • By Medication: Anti-depressants, Anti-anxiety, Mood Stabilizing Medication, Antipsychotic Medications.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Allergan plc, Eli Lilly and Company, VistaGen Therapeutics, Sanofi S.A, Novartis International AG, Mylan N.V., Amneal Pharmaceuticals LLC, Cipla Ltd, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Lupin Limited, Janssen Pharmaceutica, Bristol Myers Squibb, and Sumitomo Dainippon Pharma Co., Ltd

Growth Drivers:
  • Increasing prevalence of various mental disorders such as depression and bipolar disorders globally
  • Key players focusing on inorganic strategies such collaborations and partnerships
Restraints & Challenges:
  • Anti-depressants can cause sexual disorders such as erectile dysfunction in male adults and antipsychotic medication leading to weight gain

Global Mental Disorder Treatment Market – Impact of Coronavirus (COVID-19)

Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency. According to the World Health Organization’s report, manifestation of coronavirus (COVID-19) has resulted in over 65.1 million infected individuals worldwide as of 4th December, 2020.

The coronavirus (COVID-19) pandemic and resulting lockdown in various countries across the globe have impacted the financial status of major companies in the mental disorder treatment market. The private healthcare sector is one of the sectors, which has been majorly impacted by the COVID-19 pandemic. The pandemic has negatively impacted the global mental disorder treatment market in various aspects such as development, production, and supply of medicines and also affected growth of the pharmaceutical businesses of various companies across the globe due to lockdowns implemented by governments of several countries. The nationwide lockdowns have led to closure of industrial establishments, except manufacturing of essential commodities and disruption in supply chain of the raw materials and drugs for therapeutic use.

Figure 2. Global Mental Disorder Treatment Market Share (%), By Region, 2020

MENTAL DISORDER TREATMENT MARKET

North America is expected to hold dominant position in the global mental disorder treatment market during the forecast period, owing to key companies focusing on inorganic strategies such as strategic collaborations for developing the treatment of various mental disorders such as depression and others. For instance, in June 2020, VistaGen Therapeutics, a pharmaceutical company in the U.S. and EverInsight Therapeutic entered into a strategic collaboration to develop and commercialize ph94b for anxiety disorders in greater China, South Korea, and Southeast Asia.

Key Players

Major players operating in the global mental disorder treatment market include Allergan plc, Eli Lilly and Company, VistaGen Therapeutics, Sanofi S.A, Novartis International AG, Mylan N.V., Amneal Pharmaceuticals LLC, Cipla Ltd, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Lupin Limited, Janssen Pharmaceutica, Bristol Myers Squibb, and Sumitomo Dainippon Pharma Co., Ltd

Frequently Asked Questions

The global mental disorder treatment market size is estimated to be valued at US$ 48.4 billion in 2020 and is expected to exhibit a CAGR of 6.6 % between 2020 and 2027.

Increasing prevalence of various mental disorders such as depression, bipolar disorders globally and key players focusing on inorganic strategies such collaborations and partnerships are expected to drive growth of the global mental disorder treatment market over the forecast period.

Depression segment is estimated to hold major market share in the global mental disorder treatment market during the forecast period, owing to an increasing prevalence of depression in individuals globally.

Anti-depressants segment is estimated to hold major market share in the global mental disorder treatment market during the forecast period, owing to rising incidence of depression in children and adults globally.

North America is estimated to generate largest revenue share in 2020 in the global mental disorder treatment market.

Anti-depressants can cause sexual disorders such as erectile dysfunction in male adults and antipsychotic medication leading to weight gain are the key factors that are expected to hamper growth of the market.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo